Botulinum toxin in esophageal motility disorders

Esophageal motility disorders affect the way the food pipe contracts, relaxes and clears swallowed material. Achalasia is the best-known condition, but clinicians also manage distal esophageal spasm, hypercontractile esophagus and esophagogastric junction outflow obstruction. Symptoms can include difficulty swallowing, chest pain, regurgitation, coughing at night and unintended weight loss.

Botulinum toxin has a targeted role in this field. Injected into selected muscles at the lower esophageal sphincter, it temporarily reduces acetylcholine-mediated contraction and may make swallowing easier. Its benefits and limitations need to be considered alongside high-resolution manometry, endoscopy, pneumatic dilation, peroral endoscopic myotomy and surgical myotomy.

How the treatment works

Botulinum neurotoxin is injected endoscopically into the lower esophageal sphincter, usually in several divided doses. By weakening excessive smooth-muscle contraction, it can lower resistance at the esophagogastric junction and improve the passage of food and liquids into the stomach.

The effect is temporary because nerve terminals gradually recover. Some people experience meaningful relief for several months, while others have a shorter response. Repeat injections can be considered, although repeated treatment may contribute to local fibrosis and make a later surgical or endoscopic myotomy technically more difficult.

Which patients may benefit

Botulinum toxin is generally most useful for people with achalasia who are older, medically frail or at increased anaesthetic risk. It may also be considered when a patient needs rapid, less invasive symptom relief or is not ready for a more definitive intervention.

For younger and fitter patients, pneumatic dilation, laparoscopic Heller myotomy or peroral endoscopic myotomy often provides more durable control. Treatment decisions depend on achalasia subtype, symptom burden, aspiration risk, anatomy, previous procedures and the person’s preferences. A specialist should confirm that symptoms arise from impaired junctional relaxation rather than reflux, narrowing, malignancy or another cause.

Diagnosis comes before injection

Upper endoscopy is important to exclude a tumour, stricture, retained food or inflammatory disease that may imitate achalasia. High-resolution manometry then measures peristalsis and sphincter relaxation, helping distinguish classic, vigorous and spastic patterns. A timed barium swallow can show delayed clearance and the characteristic tapering at the gastroesophageal junction.

In Australia, assessment may occur through a public hospital gastroenterology service or a private specialist practice in Sydney, Melbourne, Brisbane or another major centre. People living in regional and remote areas may need to travel for manometry and therapeutic endoscopy, so coordinating investigations can reduce repeated long-distance trips and delays.

Benefits and practical limitations

Clinical studies show that botulinum toxin can improve dysphagia and regurgitation in the short term, with relatively low immediate procedural risk. It may be particularly valuable when a patient cannot tolerate a longer operation or needs temporary relief while another treatment is arranged.

The main limitation is durability. Symptoms commonly return as the neuromuscular effect fades, and repeat procedures may be required. Chest discomfort, reflux, local bleeding, infection and inadequate response are possible. Aspiration remains a concern in people with substantial esophageal retention, especially if they eat late at night or lie down soon after meals.

Safety and Australian regulation

Use of botulinum toxin for esophageal achalasia is commonly regarded as an off-label application rather than a routine cosmetic or approved indication. Australian clinicians must work within the Therapeutic Goods Administration framework, hospital policies and professional standards, while explaining the evidence, alternatives, expected duration and possible risks during consent.

Access also varies between state health services, private hospitals and local formularies. The medicine may be available through a hospital pharmacy, but procedural fees, anaesthesia, pathology and follow-up can affect the total cost. Patients should clarify whether their care is public or private and how Medicare, private insurance and specialist billing apply before the procedure.

Where it fits in ongoing care

Botulinum toxin should be viewed as one part of a longer management plan. Follow-up may include symptom scoring, weight checks, nutritional review and repeat testing if swallowing deteriorates. Persistent regurgitation, recurrent chest infections or dehydration requires prompt medical assessment.

Education helps patients recognise patterns that worsen symptoms. Smaller meals, careful chewing and remaining upright after eating may reduce discomfort, while very late dinners can aggravate nocturnal regurgitation. The treatment and research discussions presented through the International Society for Diseases of the Esophagus remain useful background for clinicians reviewing evolving approaches; the archived congress registration details also reflect the educational scope of the 2021 World Congress for Esophageal Diseases.

For an Australian patient, the next step is to arrange review with a gastroenterologist who can confirm the diagnosis with endoscopy and high-resolution manometry, then document whether botulinum toxin is the safest and most appropriate option.